IMU-856
immunic therapeutics
['$imux', 'immunic']
today, 9:30am-4:00pm ct, at , dr. franziska buri nek, senior medical director at $imux, presents an e-poster, entiteled: "first-in-human trial of #imu856, an orally available regulator of barrier function for the treatment of #celiacdisease". #ddw #ddw2023 #immunic 
Immunic (Nasdaq: IMUX) is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases